27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Johnson & Johnson (NYSE:JNJ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ahead for the pharma giant.
On Thursday, Credit Suisse reinstated coverage of Johnson & Johnson stock with an Outperform rating and $148 price target. According to Divan, Johnson & Johnson has several key growth drivers ahead.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
“Based on channel checks and detailed modeling we have done across various therapeutic areas, we see opportunities for significant upside from assets such as Xarelto, Darzalex and Imbruvica,” Divan wrote. Related Link:
He noted that these growth drivers are not necessarily a result of the Actelion buyout. In fact, Divan said that at $29.1 billion, Johnson & Johnson likely overpaid for Actelion. Still, the deal certainly adds another long-term growth avenue for Johnson & Johnson.
In the near term, Johnson & Johnson has two potentially bullish catalysts ahead.
First, the company is expected to release COMPASS data for Xarelto at the European Society of Cardiology conference on August 29. Shortly thereafter, Johnson & Johnson has the PDUFA date for sirukumab in mod-sensitive rheumatoid arthritis on Sept. 22.
In addition, investors should look for the addition of more Remicade biosimilars in the second half of 2017, Divan said.
Over the long term, Divan sees the pharma business as the major growth driver. Credit Suisse estimates 5.8 percent compound annual growth from the pharma business through 2021 compared to just 3.7 percent annual growth for the medical devices business and 3.1 percent annual growth from the consumer business.
Credit Suisse’s $148 price target is based on 18.5x the company’s 2018 EPS forecast of $7.79.
__________Image Credit: By Raysonho @ Open Grid Scheduler / Grid Engine - Own work, CC0, via Wikimedia Commons27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.